Imaging of hepatocellular carcinoma: Diagnosis, staging and treatment monitoring

Cancer Imaging

Volumn 12, Issue 3, 2012, Pages 530-547

  Hennedige, Tiffany ^a   Venkatesh, Sudhakar Kundapur ^a,b  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b MAYO CLINIC   (United States)

Author keywords

CT; Diagnosis; Hepatocellular carcinoma; Locoregional treatment; MRI

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ABLATION THERAPY; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER THERAPY; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; ECHOGRAPHY; ELASTOGRAPHY; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PORTAL VEIN THROMBOSIS; POSITRON EMISSION TOMOGRAPHY; REVIEW; TREATMENT RESPONSE; TUMOR ABLATION;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84874456787     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2012.0044     Document Type: Review

References (109)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917. doi:10.1002/ ijc.25516. PMid:21351269.
2. Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010; 4: 439-474. doi:10.1007/s12072-010-9165-7. PMid:20827404.
3. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430. doi:10.1016/S0168- 8278(01)00130-1. PMid:11592607. (Pubitemid 32844200)
4. Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236. doi:10.1002/hep.20933. PMid:16250051.
5. European Association for the Study of the Liver, European Organization for Research and Treatment of Cancer. EASLEORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943.
6. Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022. doi:10.1002/hep.24199. PMid:21374666.
7. Simonetti RG, Camma C, Fiorello F, Politi F, DAmico G, Pagliaro L. Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci 1991; 36: 962-972. doi:10.1007/BF01297149. PMid:1649041.
8. Ferenci P, Fried M, Labrecque D, et al. World Gastroenterology Organisation global guideline. Hepatocellular carcinoma (HCC): a global perspective. J Gastrointestin Liver Dis 2010; 19: 311-317. PMid:20922197.
9. Polesel J, Zucchetto A, Montella M, et al. The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann Oncol 2009; 20: 353-357. doi:10.1093/annonc/mdn565. PMid:18723550.
10. Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 2010; 15(Suppl 4): 14-22. doi:10.1634/theoncologist.2010-S4-14. PMid:21115577.
11. Montella M, Crispo A, Giudice A. HCC, diet and metabolic factors. Hepat Mon 2011; 11: 159-162. PMid:22087137.
12. El-Serag HB. Translational research: the study of community effectiveness in digestive and liver disorders. Gastroenterology 2007; 132: 8-10. doi:10.1053/j.gastro.2006.11.038. PMid:- 17241853. (Pubitemid 46108760)
13. Trichopoulos D, Bamia C, Lagious P, et al. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. J Natl Cancer Inst 2011; 103: 1686-1695. doi:10.1093/jnci/djr395. PMid:22021666.
14. Marcellin P, Pequignot F, Delarocque-Astagneau E, et al. Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIC coinfection and alcohol consumption. J Hepatol 2008; 48: 200-207. doi:10.1016/ j.jhep.2007.09.010. PMid:18086507.
15. Dragani TA. Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol 2010; 52: 252-257. doi:10.1016/ j.jhep.2009.11.015. PMid:20022654.
16. Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol 2003; 39: 1076-1084. doi:10.1016/S0168- 8278(03)00349-0. PMid:14642630. (Pubitemid 37523784)
17. Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Ailment Pharmacol Ther 2009; 30: 37-47. doi:10.1111/j.1365-2036.2009.04014.x.
18. Zhang B, Yang B. Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer. J Med Screen 1999; 6: 108-110. PMid:10444731. (Pubitemid 29320849)
19. Lok AS, Sterling RK, Everhart JE, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010; 138: 493-502. doi:10.1053/j.gastro.2009.10. 031. PMid:- 19852963.
20. Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 2008; 247: 311-330. doi:10.1148/ radiol.2472061331. PMid:18430871.
21. Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2008; 6: 1418-1424. doi:10.1016/j.cgh.2008.08.005. PMid:18848905.
22. Leoni S, Piscaglia F, Golferi R, et al. The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. Am J Gastroenterol 2010; 105: 599-609. doi:10.1038/ ajg.2009.654. PMid:19935786.
23. Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008; 47: 97-104. doi:10.1002/hep.21966. PMid:18069697. (Pubitemid 351171046)
24. Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis 2005; 25: 133-142. doi:10.1055/ s-2005-871193. PMid:15918142. (Pubitemid 40781066)
25. Rimola J, Forner A, Reig M, et al. Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology 2009; 50: 791-198. doi:10.1002/hep.23071. PMid:19610049.
26. Bolondi L, Gaiani S, Celli N, et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 2005; 42: 27-34. doi:10.1002/hep.20728. PMid:15954118. (Pubitemid 40911308)
27. Sangiovanni A, Manini MA, Iavarone M, et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010; 59: 638-644. doi:10.1136/gut.2009.187286. PMid:19951909.
28. Luca A, Caruso S, Milazzo M, et al. Multidetector-row computed tomography (MDCT) for the diagnosis of hepatocellular carcinoma in cirrhotic candidates for liver transplantation: prevalence of radiological vascular patterns and histological correlation with liver explants. Eur Radiol 2010; 20: 898-907. doi:10.1007/ s00330-009-1622-0. PMid:19802612.
29. Choi BI, Lee JM. Advancement in HCC imaging: diagnosis, staging and treatment efficacy assessments: imaging diagnosis and staging of hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 2010; 17: 369-373. doi:10.1007/s00534- 009-0227-y. PMid:- 19967573.
30. Shah ZK, McKernan MG, Hahn PF, Sahani DV. Enhancing and expansile portal vein thrombosis: value in the diagnosis of hepatocellular carcinoma in patients with multiple hepatic leisons. AJR Am J Roentgenol 2007; 188: 1320-1323. doi:10.2214/ AJR.06.0134. PMid:17449777. (Pubitemid 46668515)
31. Murakami T, Kim T, Hori M, Federle MP. Double arterial phase multi-detector row helical CT for detection of hypervascular hepatocellular carcinoma. Radiology 2003; 229: 931-932. doi:10.1148/radiol.2293030590. PMid:14657326. (Pubitemid 37467605)
32. Schima W, Hammerstingl R, Catalano C, et al. Quadruple-phase MDCT of the liver in patients with suspected hepatocellular carcinoma: effect of contrast material flow rate. AJR Am J Roentgenol 2006; 186: 1571-1579. doi:10.2214/AJR.05.1226. PMid:16714645. (Pubitemid 46112519)
33. Kim SK, Lim JH, Lee WJ, et al. Detection of hepatocellular carcinoma: comparison of dynamic three-phase computed tomography images and four-phase computed tomography images using multidetector row helical computed tomography. J Comput Assist Tomogr 2002; 26: 691-698. doi:10.1097/00004728-200209000- 00005. PMid:12439300. (Pubitemid 35423369)
34. Laghi A, Iannaccone R, Rossi P, et al. Hepatocellular carcinoma: detection with triple-phase multi-detector row helical CT in patients with chronic hepatitis. Radiology 2003; 226: 543-549. doi:10.1148/radiol.2262012043. PMid:12563152. (Pubitemid 36313447)
35. Ippolito D, Sironi S, Pozzi M, et al. Perfusion CT in cirrhotic patients with early stage hepatocellular carcinoma: assessment of tumor-related vascularization. Eur J Radiol 2010; 73: 148-152. doi:10.1016/j.ejrad.2008.10. 014. PMid:19054640.
36. Sahani DV, Holalkere NS, Mueller PR, Zhu AX. Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue-initial experience. Radiology 2007; 243: 736-743. doi:10.1148/ radiol.2433052020. PMid:17517931. (Pubitemid 46799427)
37. Zhu AX, Holalkere NS, Muzihansky A, Horgan K, Sahani DV. Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Oncologist 2008; 13: 120-125. doi:10.1634/theoncologist.2007-0174. PMid:18305056. (Pubitemid 351342575)
38. Ippolito D, Sironi S, Pozzi M, et al. Hepatocellular carcinoma in cirrhotic liver disease: functional computed tomography with perfusion imaging in the assessment of tumor vascularization. Acad Radiol 2008; 15: 919-927. doi:10.1016/j.acra.2008.02.005. PMid:18572129. (Pubitemid 352033551)
39. Okada M, Kim T, Murakami T. Hepatocellular nodules in liver cirrhosis: state of the art CT evaluation (perfusion CT/volume helical shuttle scan/dual-energy CT, etc.). Abdom Imaging 2011; 36: 273-281. doi:10.1007/s00261-011-9684-2. PMid:- 21267563.
40. Kelekis NL, Semelka RC, Worawattanakul S, et al. Hepatocellular carcinoma in North America: a multi-institutional study of appearance on T1-weighted, T2-weighted, and serial gadolinium- enhanced gradient-echo images. AJR Am J Roentgenol 1998; 170: 1005-1013. PMid:9530051. (Pubitemid 28172890)
41. Hussain HK, Syed I, Nghiem HV, et al. T2-weighted MR imaging in the assessment of cirrhotic liver. Radiology 2004; 230: 637-644. doi:10.1148/radiol.2303020921. PMid:14739306. (Pubitemid 38252856)
42. Ebara M, Fukuda H, Kojima Y, et al. Small hepatocellular carcinoma: relationship of signal intensity to histopathologic findings and metal content of the tumor and surrounding hepatic parenchyma. Radiology 1999; 210: 81-88. PMid:9885591. (Pubitemid 29004287)
43. Mitchell DG, Palazzo J, Hann HW, Rifkin MD, Burk DL Jr, Rubin R. Hepatocellular tumors with high signal on T1-weighted MR images: chemical shift MR imaging and histologic correlation. J Comput Assist Tomogr 1991; 15: 762-769. doi:10.1097/ 00004728-199109000-00007. PMid:1653279.
44. Imai Y, Murakami T, Yoshida S, et al. Superparamagnetic iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading. Hepatology 2000; 32: 205-212. doi:10.1053/jhep.2000.9113. PMid:10915725. (Pubitemid 30614651)
45. Yoo HJ, Lee JM, Lee JY, et al. Additional value of SPIOenhanced MR imaging for the noninvasive imaging diagnosis of hepatocellular carcinoma in cirrhotic liver. Invest Radiol 2009; 44: 800-807. doi:10.1097/RLI. 0b013e3181bc271d. PMid:- 19838119.
46. Lee DH, Kim SH, Lee JM, et al. Diagnostic performance of multidetector row computed tomography, superparamagnetic iron oxide-enhanced magnetic resonance imaging, and dual-contrast magnetic resonance imaging in predicting the appropriateness of a transplant recipient based on Milan criteria: correlation with histopathological findings. Invest Radiol 2009; 44: 311-321. doi:10.1097/RLI.0b013e31819c9f44. PMid:19462486.
47. Nasu K, Kuroki Y, Tsukamoto T, Nakajima H, Mori K, Minami M. Diffusion-weighted imaging of surgically resected hepatocellular carcinoma: imaging characteristics and relationship among signal intensity, apparent diffusion coefficient, and histopathologic grade. AJR Am J Roentgenol 2009; 193: 438-444. doi:10.2214/AJR.08.1424. PMid:19620441.
48. Kogita S, Imai Y, Okada M, et al. Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol 2010; 20: 2405-2413. doi:10.1007/s00330-010-1812- 9. PMid:- 20490505.
49. Motosugi U, Ichikawa T, Sou H, et al. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. Radiology 2010; 256: 151-158. doi:10.1148/radiol.10091885. PMid:- 20574092.
50. Sano K, Ichikawa T, Motosugi U, Sou H, Muhi AM, Matsuda M. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic-acid-enhanced MR imaging. Radiology 2011; 261: 834-844. doi:10.1148/radiol.11101840. PMid:21998047.
51. Lee JM, Zech CJ, Bolondi L, et al. Consensus report of the 4th international forum for gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid magnetic resonance imaging. Korean J Radiol 2011; 12: 403-415. doi:10.3348/kjr.2011.12.4.403. PMid:21852900.
52. Ichikawa T, Saito K, Yoshioka N, et al. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol 2010; 45: 133-141. doi:10.1097/RLI.0b013e3181caea5b. PMid:20098330.
53. Lee SA, Lee CH, Jung WY, et al. Paradoxical high signal intensity of hepatocellular carcinoma in the hepatobiliary phase of Gd- EOB-DTPA enhanced MRI: initial experience. Magn Reson Imaging 2011; 29: 83-90. doi:10.1016/j.mri.2010.07.019. PMid:20832227.
54. Tsuboyama T, Onishi H, Kim T, et al. Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic-acid-enhanced MR imaging-correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 2010; 255: 824-833. doi:10.1148/radiol. 10091557. PMid:20501720.
55. Kim MJ. Current limitations and potential breakthroughs for the early diagnosis of hepatocellular carcinoma. Gut Liver 2011; 5: 15-21. doi:10.5009/gnl.2011.5.1.15. PMid:21461067.
56. Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology 2009; 250: 466-473. doi:10.1148/radiol.2502072222. PMid:19188315.
57. Naganawa S, Kawai H, Fukatsu H, et al. Diffusion-weighted imaging of the liver: technical challenges and prospects for the future. Magn Reson Med Sci 2005; 4: 175-186. doi:10.2463/ mrms.4.175. PMid:16543702.
58. Piana G, Trinquart L, Meskine N, Barrau V, Beers BV, Vilgrain V. New MR imaging criteria with a diffusion-weighted sequence for the diagnosis of hepatocellular carcinoma in chronic liver diseases. J Hepatol 2011; 55: 126-132. doi:10.1016/ j.jhep.2010.10.023. PMid:21145857.
59. Vandecaveye V, De Keyzer F, Verslype C, et al. Diffusionweighted MRI provides additional value to conventional dynamic contrast-enhanced MRI for detection of hepatocellular carcinoma. Eur Radiol 2009; 19: 2456-2466. doi:10.1007/s00330- 009-1431-5. PMid:19440718.
60. Kamel IR, Bluemke DA, Ramsey D, et al. Role of diffusionweighted imaging in estimating tumour necrosis after chemoembolization of hepatocellular carcinoma. AJR Am J Roentgenol 2003; 181: 708-710. PMid:12933464. (Pubitemid 37021839)
61. Taouli B, Koh DM. Diffusion-weighted MR imaging of the liver. Radiology 2010; 254: 47-66. doi:10.1148/radiol.09090021. PMid:20032142.
62. Le Moigne F, Durieux M, Bancel B, et al. Impact of diffusionweighted MR imaging on the characterization of small hepatocellular carcinoma in the cirrhotic liver. Magn Reson Imaging 2012; 30: 656-665. doi:10.1016/j.mri.2012. 01.002. PMid:22459435.
63. Xu PJ, Yan FH, Wang JH, Shan Y, Ji Y, Chen CZ. Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver. J Comput Assist Tomogr 2010; 34: 506-512. doi:10.1097/RCT.0b013e3181da3671. PMid:20657216.
64. Park MS, Kim S, Patel J, et al. Hepatocellular carcinoma: Detection with diffusion-weighted vs. contrast-enhanced MRI in pre-transplant patients. Hepatology 2012; 56: 140-148. doi:10.1002/hep.25681.
65. Xu PJ, Yan FH, Wang JH, et al. The value of breath-hold diffusion- weighted imaging in small hepatocellular carcinoma lesion (5 or -3 cm) detection. Zhonghua Yi Xue Za Zhi 2009; 89: 592-596. PMid:19595157.
66. Taouli B, Ehman RL, Reeder SB. Advanced MRI methods for assessment of chronic liver disease. AJR Am J Roentgenol 2009; 193: 14-27. doi:10.2214/AJR.09.2601. PMid:19542391.
67. Yin M, Talwalkar JA, Glaser KJ, et al. A preliminary assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 2007; 5: 1207-1213. doi:10.1016/ j.cgh.2007.06.012. PMid:17916548.
68. Huwart L, van Beers BE. MR elastography. Gastroenterol Clin Biol 2008; 32(Suppl. 1): 68-72. doi:10.1016/S0399- 8320(08)73995-2. PMid:18973848.
69. Venkatesh SK, Yin M, Glockner JF, et al. MR elastography of liver tumours: preliminary results. AJR Am J Roentgenol 2008; 190: 1534-1540. doi:10.2214/AJR.07.3123. PMid:18492904. (Pubitemid 351798532)
70. Lencioni R, Piscaglia F, Bolondi L. Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. J Hepatol 2008; 48: 848-857. doi:10.1016/j.jhep.2008.02.005. PMid:18328590.
71. Jang HJ, Kim TK, Burns PN, Wilson SR. Enhancement patterns of hepatocellular carcinoma at contrast-enhanced US: comparison with histologic differentiation. Radiology 2007; 244: 898-906. doi:10.1148/radiol.2443061520. PMid:17709836. (Pubitemid 47292103)
72. Lencioni R, Pinto F, Armillotta N, Bartolozzi C. Assessment of tumor vascularity in hepatocellular carcinoma: comparison of power Doppler US and color Doppler US. Radiology 1996; 201: 353-358. PMid:8888222. (Pubitemid 26357625)
73. Lencioni R, Mascalchi M, Caramella D, Bartolozzi C. Small hepatocellular carcinoma: differentiation from adenomatous hyperplasia with color Doppler US and dynamic Gd-DTPAenhanced MR imaging. Abdom Imaging 1996; 21: 41-48. doi:10.1007/s002619900007. PMid:8672971.
74. Lee JM, Trevisani F, Vilgrain V, Wald C. Imaging diagnosis and staging of hepatocellular carcinoma. Liver Transpl 2011; 17 (Suppl 2): S34-43.
75. Rimola J, Forner A, Reig M, et al. Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology 2009; 50: 791-798. doi:10.1002/hep.23071. PMid:19610049.
76. Gheorghe L, Iacob S, Georghe C. Real time sonoelastography- a new application in the field of liver disease. J Gastrointestin Liver Dis 2008; 17: 469-474. PMid:19104713.
77. Rustemovic N, Hrstic I, Opacic M, et al. EUS elastography in the diagnosis of focal liver lesions. Gastrointest Endosc 2007; 66: 823-824. PMid:17681503.
78. Gheorghe L, Iacob S, Iacob R, et al. Real time elastography- a non-invasive diagnostic method of small hepatocellular carcinoma in cirrhosis. J Gastrointestin Liver Dis 2009; 18: 439-446. PMid:20076816.
79. Kwon HJ, Kang MJ, Cho JH, et al. Acoustic radiation force impulse elastography for hepatocellular carcinoma-associated radiofrequency ablation. World J Gastroenterol 2011; 17: 1874-1878. doi:10.3748/wjg.v17.i14.1874. PMid:21528062.
80. Heide R, Strobel D, Bernatik T, Goertz RS. Characterization of focal liver lesions (FLL) with acoustic radiation force impulse (ARFI) elastometry. Ultraschall Med 2010; 31: 405-409. doi:10.1055/s-0029-1245565. PMid:20652853.
81. Gallotti A, DOnofrio M, Romanini L, Cantosani V, Pozzi Mucelli R. Acoustic radiation force impulse (ARFI) ultrasound imaging of solid focal liver lesions. Eur J Radiol 2012; 81: 451-455. doi:10.1016/j.ejrad.2010.12.071. PMid:21330078.
82. Ho CL, Chen S, Yeung DW, Cheng TK. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 2007; 48: 902-909. doi:10.2967/jnumed.106.036673. PMid:17504862. (Pubitemid 46909918)
83. Sorensen M, Frisch K, Bender D, Keiding S. The potential use of 2-[18F]fluoro-2-deoxy-D-galactosis as a PET/CT tracer for detection of hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2011; 38: 1723-1731. doi:10.1007/s00259-011-1831-z. PMid:- 21553087.
84. Nagamachi S, Czernin J, Kim AS, et al. Reproducibility of measurements of regional resting and hyperemic myocardial blood flow assessed with PET. J Nucl Med 1996; 37: 1626-1631. PMid:8862296. (Pubitemid 26337164)
85. Delbeke D, Martin WH. Update of PET and PET/CT for hepatobiliary and pancreatic malignancies. HPB (Oxford) 2005; 7: 166-179. doi:10.1080/ 13651820510028909. (Pubitemid 41535846)
86. Park JW, Kim JH, Kim SK, et al. A prospective evaluation of 18- F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med 2008; 49: 1912-1921. doi:10.2967/jnumed.108.055087. PMid:18997056.
87. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008; 134: 1752-1763. doi:10.1053/j.gastro.2008.02.090. PMid:- 18471552. (Pubitemid 351615415)
88. Stefaniuk P, Cianciara J, Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol 2010; 16: 418-424. doi:10.3748/wjg.v16.i4.418. PMid:20101765.
89. Heo CK, Woo MK, Yu DY, et al. Identification of autoantibody against fatty acid synthase in hepatocellular carcinoma muse model and its application to diagnosis of HCC. Int J Oncol 2010; 36: 1453-1459. PMid:20428769.
90. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338. doi:10.1055/s-2007-1007122. PMid:10518312.
91. Figueras J, Ibanez L, Ramos E, et al. Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: results of a multicenter study. Liver Transpl 2001; 7: 877-883. doi:10.1053/jlts.2001. 27856. PMid:11679986. (Pubitemid 33040462)
92. Deshpande R, OReilly D, Sherlock D. Improving outcomes with surgical resection and other ablative therapies in HCC. Int J Hepatol 2011; doi:10.4061/2011/686074.
93. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004; 127: S179-188. doi:10.1053/j.gastro.2004.09. 032. PMid:15508083. (Pubitemid 39423386)
94. Hanje AJ, Yao FY. Current approach to down-staging of hepatocellular carcinoma prior to liver transplantation. Curr Opin Organ Transplant 2008; 13: 234-240. doi:10.1097/ MOT.0b013e3282fc2633. PMid:18685309.
95. Lencioni R, de Baere T, Burrel M, et al. Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded DC bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol 2012; 35: 980-985. doi:10.1007/s00270-011-0287-7. PMid:22009576.
96. van Malenstein H, Maleux G, Vandecaveye V, et al. A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie 2011; 34: 368-376. doi:10.1159/000329602. PMid:21734423.
97. Vogl TJ, Nour-Eldin NE, Emad-Eldin S, et al. Portal vein thrombosis and arterioportal shunts: effects on tumour response after chemoembolization of hepatocellular carcinoma. World J Gastroenterol 2011; 17: 1267-1275. doi:10.3748/ wjg.v17.i10.1267. PMid:21455325.
98. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60. doi:10.1055/s-0030- 1247132. PMid:20175033.
99. Schima W, Ba-Ssalamah A, Kurtaran A, Schindl M, Gruenberger T. Post-treatment imaging of liver tumours. Cancer Imaging 2007; 7(A): S28-36. (Pubitemid 350143144)
100. Guan YS, Sun L, Zhou XP, Li X, Zheng XH. Hepatocellular carcinoma treatment with interventional procedures: CT and MRI follow-up. World J Gastroenterol 2004; 10: 3543-3548. PMid:15534903. (Pubitemid 39619265)
101. Choi D, Lim HK, Kim SH, et al. Assessment of therapeutic response in hepatocellular carcinoma treated with percutaneous radio frequency ablation: comparison of multiphase helical computed tomography and power Doppler ultrasonography with a microbubble contrast agent. J Ultrasound Med 2002; 21: 391-401. PMid:11934096. (Pubitemid 34259900)
102. Shibata T, Iimuro Y, Yamamoto Y, et al. Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology 2002; 223: 255-262.
103. Choi SH, Lee JM, Yu NC, et al. Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate dimeglumine-enhanced MRI. AJR Am J Roentgenol 2008; 191: 529-536. doi:10.2214/AJR.07.2565. PMid:18647927.
104. Kim YK, Kim CS, Chung GH, et al. Comparison of gadobenate dimeglumine-enhanced dynamic MRI and 16-MDCT for the detection of hepatocellular carcinoma. AJR Am J Roentgenol 2006; 186: 149-157. doi:10.2214/AJR.04.1206. PMid:- 16357395.
105. Taouli B, Krinsky GA. Diagnostic imaging of hepatocellular carcinoma in patients with cirrhosis before liver transplantation. Liver Transpl 2006; 12(Suppl 2): S1-7. doi:10.1002/lt.20935. PMid:17051556. (Pubitemid 44742515)
106. Kamel IR, Reyes DK, Liapi E, Bluemke DA, Geschwind JF. Functional MR imaging assessment of tumour response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2007; 18: 49-56. doi:10.1016/j.jvir.2006.10.005. PMid:17296704. (Pubitemid 46616678)
107. Dierckx R, Maes A, Peeters M, Van De Wiele C. FDG PET for monitoring response to local and loco regional therapy in HCC and liver metastases. Q J Nucl Med Mol Imaging 2009; 53: 336-342. PMid:19521313.
108. Lin CY, Chen JH, Liang JA, Lin CC, Jeng LB, Kao CH. 18FFDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: a systematic review and meta-analysis. Eur J Radiol 2012; 81: 2417-2422. doi:10.1016/j.ejrad.2011.08.004. PMid:21899970.
109. Paudyal B, Oriuchi N, Paudyal P, et al. Early diagnosis of recurrent hepatocellular carcinoma with 18F-FDG PET after radiofrequency ablation therapy. Oncol Rep 2007; 18: 1469-1473. PMid:17982632.